Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1 Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 69 pembrolizumab 48 Prednisone 43 Nivolumab 40 enzalutamide 38 Gemcitabine 37 Sunitinib 36 Cyclophosphamide 29 Radiotherapy 26 Magnetic Resonance Spectroscopy 26 Leuprolide 25 Abiraterone Acetate 25 Sorafenib 23 Everolimus 23 Cisplatin 23 bicalutamide 19 atezolizumab 18 Carboplatin 18 Bevacizumab 18 avelumab 17 Radiosurgery 17 Goserelin 17 Interleukin-2 16 abiraterone 15 fludarabine 14 Doxorubicin 14 olaparib 13 durvalumab 13 cabozantinib 13 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Genes × Genitourinary × Clear all

NCT03152448 2022-06-13

P-PROVE

Myriad Genetic Laboratories, Inc.

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡